Meet our experts

Jenny Barnett, PhD
Chief Scientific Officer

As CSO, Jenny is responsible for ensuring that all our neuroscience products and services meet the highest scientific standards, as well as the practical needs of researchers, doctors and patients.  Jenny joined Cambridge Cognition in 2008 and has worked in a variety of roles across the clinical trials and healthcare arms of the business. She led research and development activities for groundbreaking products such as CANTAB Mobile, an iPad-based medical device used to test for the first signs of Alzheimer’s disease, and Cognition Kit, a mobile and wearables platform for the remote monitoring of brain health.

Jenny has an MA in Experimental Psychology from Oxford University, a PhD in psychiatric epidemiology from the University of Cambridge, and completed post-doctoral work at Massachusetts General Hospital and the Broad Institute of Harvard and MIT. She is an Honorary Research Fellow at the University of Cambridge Department of Psychiatry, a team member of the Oulu University Northern Finland Birth Cohorts, and the author of more than 50 academic publications covering topics ranging from psychology and neuroscience to genetics and health economics. 

Kenton Zavitz

Kenton Zavitz, PhD
Director of Clinical Affairs

Kenton has over 16 years of biotechnology and pharmaceutical experience with involvement in all aspects of the industry from drug discovery and clinical development through to pre-commercialization. Prior to joining Cambridge Cognition, Kenton served as Chief Scientific Officer for New Mexico-based biotech Zocere Inc. where he worked on developing a neuroprotectant drug designed to combat brain injury resulting from stroke. He currently serves on the Scientific Advisory Board for Exonate Limited, a start-up founded in 2013 at the University of Nottingham.  From 1998 to 2012, Kenton worked at Myriad Pharmaceuticals, Inc. in Salt Lake City and served in a variety of roles including Senior Director of Clinical Affairs, Chief Scientist of the tarenflurbil clinical development program (an investigational drug for the treatment of Alzheimer’s disease, developed through Phase 3), Director of Neurodegeneration Therapeutics Discovery and Director of Strategic In-licensing and Scientific Evaluation.  Kenton received his PhD in Biochemistry and Molecular Biology from The Sloan-Kettering Division of the Weill Cornell Graduate School of Medical Sciences in New York City. He was a Postdoctoral Fellow at the UCLA School of Medicine and was awarded fellowships from the Leukemia Society of America and the Jane Coffin Childs Memorial Fund for Medical Research.

John Evenden, PhD
Director of Science

John has received PhDs in Experimental Psychology from the University of Cambridge and in Medical Pharmacology from Uppsala University in Sweden.   Dr Evenden was a Post-Doctoral Research Fellow at Harvard University and also did post-doctoral research at Cambridge University, where he was a member of the team which designed the CANTAB.  Dr Evenden spent twenty years in the pharmaceutical industry at Merck Sharp and Dohme, AB Astra and AstraZeneca, where he led pre-clinical behavioral pharmacology teams and served as a project leader for drug discovery projects focused on novel targets for antidepressant medications. 


Dr Evenden has been a pioneer in developing new translational behavioral test procedures in the areas of cognition and impulsive behavior.  In 2008 he founded an independent company to develop web-based neuropsychological test procedures for impulsivity, executive functions and their modulation by emotions, before joining Cambridge Cognition in 2015 as Director of Science.  Dr Evenden is also currently adjunct professor in the Dept. of Psychiatry and Behavioral Science at Temple University Medical School and the Dept. of Psychology at Villanova University.

Francesca Cormack, PhD
Director of Research and Innovation


Francesca is Director of Research and Innovation at Cambridge Cognition and has extensive experience of statistics, cognitive neuroscience and cognitive test development in clinical populations. Since joining Cambridge Cognition in 2014, Francesca has been involved providing scientific and analytic consultancy to researchers and healthcare practitioners. Francesca leads internal research efforts using neuroscience and data analytics to guide the development of new cognitive testing technology.


Francesca obtained a PhD in Dementia with Lewy Bodies at Newcastle, followed by post-doctoral and academic positions at University College London and Cambridge. She maintains academic collaborations focused on neurological disorders, ageing and dementia.

Rosemary Abbott, PhD
Principal Statistical Analyst


Rosemary has a PhD from the University of Leicester and is a Fellow of the Royal Statistical Society. Rosemary has extensive experience in the practical and theoretical application of statistics across the academic, public and commercial sectors.  Throughout her career Rosemary has worked in analytic roles and joined Cambridge Cognition in 2012 after working as a research methodologist at the University of Cambridge, Department of Psychiatry, and as Head of Statistics at Leicestershire Constabulary.

As Principal Statistical Analyst, Rosemary leads on the provision of statistical consultancy within Cambridge Cognition, and the analyses of cognitive data for our pharmaceutical, biotechnology and academic collaborators. 


Rosemary is particularly interested in approaches to longitudinal data analyses and has published widely on psychiatric epidemiology and the application of modern psychometric methods to psychological and psychiatric data.  

Nick Taptiklis
Head of Technology Strategy


As Head of Technology Strategy, Nick develops innovative technological solutions to scientific and health challenges; exploring new methods for measuring cognition at scale by leveraging consumer hardware, crowd-sourcing, cloud infrastructure and analytics.


Since joining Cambridge Cognition in 2010, Nick has brought experience in translating scientific research into innovative mobile products and solutions. 


He is interested in helping realise the potential for mobile and wearable technology to transform the treatment of mental health disorders. He has pioneered new methods of cognitive testing outside of the laboratory using off-the-shelf consumer devices, and has developed integrated cloud-based analytic solutions combining physiological and cognitive data.


Nick’s past experience includes machine-vision, 3D database visualisation, voice recognition, security, bluetooth content distribution, and many consumer-focused mobile apps.

Charlotte R Housden

Charlotte R Housden, PhD
Senior Scientist

Charlotte Housden heads the biotechnology and research business unit at Cambridge Cognition. Before joining the company in 2012, Charlotte completed a BSc in Psychology at the University of Exeter, an MSc in Cognitive Neuroscience at UCL, and a PhD at the Department of Psychiatry, University of Cambridge, where she still holds an honorary research fellowship position. 

Her scientific interests include the use of cognition as a biomarker in neurological and neurodegenerative disorders, as well as the pharmacological remediation of cognitive symptoms. 

Kiri Granger, PhD
Senior Scientist


Following a PhD in Cognitive and Behavioural Neuroscience at the University of Nottingham Kiri joined Cambridge Cognition as Scientist in 2015. Her areas of expertise include the profiles of cognitive impairment and treatment of psychotic and affective related disorders. Kiri provides end-to-end scientific consultancy and support to pharmaceutical and biotechnology companies to optimise study design and success in the development of safe and effective compounds. Being a Fellow of the Royal Statistical Society, Kiri provides consultancy for data analysis and interpretation of study endpoints. Her other research interests include the use of cognitive remediation therapy as a synergistic treatment for CNS disorders.

Matthew Hobbs, MSc
Operational Scientist


Following a BSc in Psychology and MSc in Cognitive Neuroscience at the University of Exeter Matt joined Cambridge Cognition in 2015. As Product Manager, he supported the development and configuration of CANTAB tasks for use in academic research and pharmaceutical industry trials. Matt brings expert understanding of product functionality to support the delivery and execution of CANTAB across all clinical trials since joining the Pharmaceutical team as an Operational Scientist in 2016. His area of expertise focuses on the effects of Methylphenidate on attentional networks and executive functioning within behavioural and neurodegenerative disorders.


Henry Galperin, PhD
Biotech and Research Sales Manager


Henry Galperin joined Cambridge Cognition in 2016 as Biotechnology and Research Sales Manager in the United States. He holds a B.A. in Psychology from Case Western Reserve University and a PhD in Cognitive Neuroscience from Brandeis University.


Henry has extensive research experience in ageing, visual perception, emotion regulation, psychophysics and electrophysiology. He has also represented manufacturers of neuroscience equipment in the USA with a focus on non-invasive brain stimulation. His interests include novel non-pharmacological interventions for central nervous system disorders and bringing translational research from the lab into the clinical sphere. 

Andy D Blackwell, PhD

Andy Blackwell, PhD
Non-Executive Director

Andy is a Non-Executive Director at Cambridge Cognition, board advisor to several other neurotech companies, and Honorary Researcher at the University of Cambridge. Andy believes that technology can transform our understanding of the environmental and biological determinants of brain health, and will empower us to achieve and maintain peak cognitive form throughout life. He has worked in the field of cognitive assessment for over 20 years and worked closely with Professors Trevor Robbins and Barbara Sahakian in the areas of cognitive neuropsychology and psychopharmacology at the University of Cambridge.

Andy's clinical experience includes Alzheimer’s disease, mild cognitive impairment, Parkinson’s disease, Huntington’s disease, stroke, OCD, ADHD and depression. Andy has published numerous papers in quality journals, including Science, American Journal of Psychiatry and Neuropsychopharmacology.

Since joining the board of Cambridge Cognition in 2007, Andy has consulted for most of the leading pharmaceutical research organizations and has worked on over 150 clinical trials of investigational drugs targeting disorders of the CNS.

Professor Trevor Robbins

Trevor Robbins PhD, CBE, FRS, FMedSci, FBPsS
Senior Consultant and Professor of Cognitive Neuroscience, University of Cambridge

Prof Robbins is the co-inventor of the CANTAB. He is Professor of Cognitive Neuroscience and Head of the Department of Experimental Psychology at the University of Cambridge. He is also Director of the Cambridge University MRC-Wellcome Trust funded Behavioural and Clinical Neuroscience Institute (BCNI), the main objective of which is to inter-relate basic and clinical research in psychiatry and neurology. Professor Robbins is a Fellow of the British Psychological Society, the Academy of Medical Sciences, and the Royal Society. He has published over 600 peer-reviewed papers and 70 chapters in scientific journals and has co-edited 6 books.

Professor Barbara Sahakian

Professor Barbara Sahakian FMedSci, FBPsS
Senior Consultant and Professor of Clinical Neuropsychology, University of Cambridge

Prof. Sahakian is the co-inventor of the CANTAB  and Professor of Clinical Neuropsychology at the University of Cambridge.  Her research is aimed at understanding the neural basis of cognitive, emotional and behavioural dysfunction in order to develop more effective pharmacological and psychological treatments. The focus of her research is in early detection, differential diagnosis and proof of concept studies using cognitive enhancing drugs. She has published over 300 papers in the area of Alzheimer’s disease, ADHD, Depression, obsessive compulsive disorder, substance abuse and Schizophrenia. 

Sam Chamberlain MB/BChir PhD MRCPsych
Consulting Psychiatrist

Sam is a Clinical Lecturer and Psychiatrist at the University of Cambridge, and an external consultant at Cambridge Cognition. His research focuses on disorders of impulsivity and compulsivity, and the neurochemical modulation of cognition. Dr Chamberlain has published over 100 peer-reviewed publications, including first-authored papers in Science, the American Journal of Psychiatry, and the Archives of General Psychiatry. He has co-authored a recent book (Clinical Guide to Obsessive Compulsive and Related Disorders, Oxford University Press) and contributed to others. He is Associate Editor at Neuroscience and Biobehavioral Reviews, and acts as reviewer for a variety of journals and organizations (including the European Commission Science Directorate). Dr Chamberlain is internationally recognised for his research work and has received various awards, including the Wyeth Award for Psychopharmacology (British Association for Psychopharmacology, 2009).

Jonathan Roiser MA (Cantab) PhD
Consultant Neuroscientist


Jonathan Roiser is Professor of Neuroscience and Mental Health at the UCL Institute of Cognitive Neuroscience, and a Wellcome Trust Senior Investigator. His research aims to understand the neural and cognitive mechanisms driving mental health problems, especially disrupted motivation in depression. He has been consultant for Cambridge Cognition since 2006.


He studied Natural Sciences at Trinity College, Cambridge, as an undergraduate and remained there for his doctorate in the Department of Psychiatry, including a year spent at the US National Institute of Mental Health (NIMH). Following post-doctoral work at the UCL Institute of Neurology he was appointed to his current faculty position in 2007, being promoted to full Professor in 2015. He has published over 100 papers and is an editor at Neuroimage: Clinical. His work is recognized internationally and he has been awarded the British Psychological Society’s Spearman Medal, the British Association for Psychopharmacology’s Senior Award, and the Philip Leverhulme Prize in recognition of his scientific achievements. He has previously held funding from the MRC, the Brain and Behavior Research Foundation and the British Academy. He founded and directs two PhD schemes: the UCL-NIMH Joint Doctoral Training Program in Neuroscience; and the UCL 4-year PhD Programme in Mental Health.